BDX Stock Forecast 2025-2026
Distance to BDX Price Targets
BDX Price Momentum
10 Quality Stocks Worth Considering Now
Researching BD (BDX) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on BDX and similar high-potential opportunities.
Latest BDX Stock Price Targets & Analyst Predictions
Based on our analysis of 22 Wall Street analysts, BDX has a bullish consensus with a median price target of $270.00 (ranging from $245.00 to $325.00). The overall analyst rating is Strong Buy (8.5/10). Currently trading at $198.71, the median forecast implies a 35.9% upside. This outlook is supported by 13 Buy, 4 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Jason Bednar at Piper Sandler, suggesting a 23.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BDX Analyst Ratings
BDX Price Target Range
Latest BDX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BDX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 7, 2025 | Barclays | Travis Steed | Overweight | Maintains | $261.00 |
| Feb 14, 2025 | Barclays | Travis Steed | Overweight | Maintains | $279.00 |
| Jan 28, 2025 | Piper Sandler | Jason Bednar | Overweight | Maintains | $280.00 |
| Oct 1, 2024 | Citigroup | Joanna Wiensch | Buy | Upgrade | $275.00 |
| Oct 1, 2024 | Evercore ISI Group | Vijay Kumar | Outperform | Maintains | $290.00 |
| Aug 2, 2024 | Raymond James | Jayson Bedford | Outperform | Maintains | $270.00 |
| Jul 26, 2024 | Stifel | Rick Wise | Buy | Maintains | $280.00 |
| Jul 11, 2024 | Citigroup | Neutral | Maintains | $0.00 | |
| Jul 10, 2024 | Citigroup | Joanna Wiensch | Neutral | Maintains | $255.00 |
| Jul 2, 2024 | Evercore ISI Group | Vijay Kumar | Outperform | Maintains | $285.00 |
| May 30, 2024 | Goldman Sachs | David Roman | Buy | Initiates | $274.00 |
| May 6, 2024 | Barclays | Travis Steed | Overweight | Maintains | $312.00 |
| Feb 5, 2024 | Barclays | Travis Steed | Overweight | Maintains | $305.00 |
| Jan 3, 2024 | Raymond James | Jayson Bedford | Outperform | Maintains | $275.00 |
| Dec 4, 2023 | Morgan Stanley | Patrick Wood | Overweight | Maintains | $280.00 |
| Nov 10, 2023 | Piper Sandler | Jason Bednar | Overweight | Maintains | $280.00 |
| Nov 10, 2023 | Raymond James | Jayson Bedford | Outperform | Maintains | $269.00 |
| Aug 21, 2023 | Citigroup | Joanna Wiensch | Neutral | Maintains | $282.00 |
| Aug 7, 2023 | Barclays | Travis Steed | Overweight | Maintains | $303.00 |
| Aug 4, 2023 | Raymond James | Lawrence Keusch | Outperform | Maintains | $304.00 |
Becton, Dickinson and Company (BDX) Competitors
The following stocks are similar to BD based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Becton, Dickinson and Company (BDX) Financial Data
Becton, Dickinson and Company has a market capitalization of $57.06B with a P/E ratio of 33.5x. The company generates $20.64B in trailing twelve-month revenue with a 8.4% profit margin.
Revenue growth is +9.8% quarter-over-quarter, while maintaining an operating margin of +15.3% and return on equity of +6.8%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Becton, Dickinson and Company (BDX) Business Model
About Becton, Dickinson and Company
Develops and manufactures medical devices and systems.
BD generates revenue through the sale of medical devices, instrument systems, and reagents across its three business segments: BD Medical, BD Life Sciences, and BD Interventional. The company serves various sectors including pharmaceuticals, hospitals, and clinical laboratories, focusing on enhancing patient safety and healthcare delivery.
With a strong emphasis on innovation and quality, BD plays a crucial role in improving medical discovery and care delivery. Headquartered in Franklin Lakes, New Jersey, the company has a significant global presence, impacting healthcare infrastructure worldwide.
Company Information
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
70,000
CEO
Mr. Thomas E. Polen Jr.
Country
United States
IPO Year
1983
Website
www.bd.comBecton, Dickinson and Company (BDX) Latest News & Analysis
The portfolio aims for increasing dividend income by investing in companies with a history of dividend growth and reinvests dividends to enhance compounding.
A focus on dividend growth and reinvestment suggests potential for steady income and compounding returns, appealing to income-focused investors seeking stability and growth.
Becton Dickinson is in early discussions to sell its $21 billion Life Sciences unit, considering various options with major medical technology and diagnostics companies.
Becton Dickinson's potential divestiture of its $21 billion Life Sciences unit could reshape its focus, impact revenue, and attract investor interest in related sectors.
BD (Becton, Dickinson and Company) will host an audio webcast on April 3, 2025, at 8 a.m. for investors and stakeholders.
BD's webcast likely includes key updates on financial performance, strategy, or product developments, which can influence stock price and investor sentiment.
Becton Dickinson is in talks to sell its $21 billion life sciences division, engaging with competitors like Thermo Fisher Scientific and Danaher, according to the Financial Times.
Becton Dickinson's potential sale of its $21 billion life sciences division could reshape market dynamics, impact stock valuations, and present acquisition opportunities for competitors.
BD (Becton, Dickinson and Company) has been recognized in Fortune's 2025 list of America's Most Innovative Companies, ranking in the top 25%.
BD's recognition in Fortune's list highlights its strong innovation, potentially boosting investor confidence and attracting more capital due to expected future growth and competitive advantage.
Best Dividend Aristocrats For April 2025
19 days agoIn 2025, Dividend Aristocrats have outperformed the S&P 500, with NOBL up 1.78%. Key performers include Consolidated Edison (+22.98%) and AbbVie (+16.61%). 29 have increased dividends by an average of 4.15%.
Dividend Aristocrats are showing strong performance and resilience, with significant dividend increases, indicating stability and potential for income-focused investors amid broader market declines.
Frequently Asked Questions About BDX Stock
What is Becton, Dickinson and Company's (BDX) stock forecast for 2025?
Based on our analysis of 22 Wall Street analysts, Becton, Dickinson and Company (BDX) has a median price target of $270.00. The highest price target is $325.00 and the lowest is $245.00.
Is BDX stock a good investment in 2025?
According to current analyst ratings, BDX has 13 Buy ratings, 4 Hold ratings, and 0 Sell ratings. The stock is currently trading at $198.71. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for BDX stock?
Wall Street analysts predict BDX stock could reach $270.00 in the next 12 months. This represents a 35.9% increase from the current price of $198.71. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Becton, Dickinson and Company's business model?
BD generates revenue through the sale of medical devices, instrument systems, and reagents across its three business segments: BD Medical, BD Life Sciences, and BD Interventional. The company serves various sectors including pharmaceuticals, hospitals, and clinical laboratories, focusing on enhancing patient safety and healthcare delivery.
What is the highest forecasted price for BDX Becton, Dickinson and Company?
The highest price target for BDX is $325.00 from at , which represents a 63.6% increase from the current price of $198.71.
What is the lowest forecasted price for BDX Becton, Dickinson and Company?
The lowest price target for BDX is $245.00 from Jason Bednar at Piper Sandler, which represents a 23.3% increase from the current price of $198.71.
What is the overall BDX consensus from analysts for Becton, Dickinson and Company?
The overall analyst consensus for BDX is bullish. Out of 22 Wall Street analysts, 13 rate it as Buy, 4 as Hold, and 0 as Sell, with a median price target of $270.00.
How accurate are BDX stock price projections?
Stock price projections, including those for Becton, Dickinson and Company, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.